early breast cancer
Conditions
Interventions
Trade Name: DENOSUMAB
Product Name: Denosumab
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Denosumab
CAS Number: 615258-40-7
Current Sponsor code: ICO-13-001
Other descriptive name
Sponsors
Institut Català d’Oncologia
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? Understand and sign Informed Consent for this study. ? Women = than 18 years, (the inclusion process will be modified to recruit at least 24 premenopausal patients). ? Capable, under investigator judgment, to understand the non-therapeutic nature of the study. ? Diagnosed with invasive breast cancer in early, curable, stage (I or II) candidate to radical surgery as first therapeutic approach. ? Her2 negative receptor status. ? Any estrogen, progesterone status (the inclusion process will be modified to recruit at least 24 patients with TNBC tumors). ? No previous systemic treatment for any malignancy. ? No ongoing treatment with denosumab or bisphosphonates ? Tumour amenable for baseline Biopsy and punch-Biopsy after excision. o Adequate Serum calcium or albumin-adjusted serum calcium = 2.0 mmol/L (8.0 mg/dL) and = 2.9 mmol/L (11.5 mg/dL) o No prior history or current evidence of osteonecrosis of the jaw o No Active dental or jaw condition which requires oral surgery, including tooth extraction. No planned invasive dental procedures ? General Laboratory test within normality or with non-relevant deviations of normality as per investigator judgment ? Patients must have a normal organ and bone marrow function as defined local standards: Leukocytes, Absolute neutrophil count, Platelets, Total bilirubin, AST/ALT/GOT/GPT, Creatinine, Creatinine clearance, Magnesium, Phosphorus. ? Subject with reproductive potential must be willing to use, in combination with her partner, 2 acceptable methods of effective contraception or practice sexual abstinence throughout the study and continue for 6 months after study duration. Subjects who are surgically sterile (eg. history of bilateral tubal ligation, hysterectomy) or whose sexual partner is sterile (eg. history of vasectomy) are not required to use additional contraceptive measures”. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 60 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: ? Invasive breast cancer non amenable to surgical excision as first therapeutic approach. ? HER2-positive Breast Cancer ? Metastatic breast cancer or other condition that recommends other treatment than surgery as the primary therapeutic approach. ? Prior systemic treatment for any malignancy. ? Treatment with denosumab contraindicated. ? Bleeding diathesis or other concomitant condition that contraindicate inclusion in the study as per investigator judgment. ? High risk of ONJ or hypocalcemia: o Inadequate Serum calcium or albumin-adjusted serum calcium 2.9 mmol/L (11.5 mg/dL) o Prior history or current evidence of osteonecrosis of the jaw ? Active dental or jaw condition which requires oral surgery, including tooth extraction. Planned invasive dental procedures. ? Subject has known sensitivity to any of the products to be administered during the study (e.g., mammalian derived products, calcium, or vitamin D). ? Subject is pregnant or breast feeding, or planning to become pregnant / breastfeed while on study through 6 months after the end of treatment. ? Subject is of child bearing potential and is not willing to use, in combination with her partner, two highly effective methods of contraception or abstinence during treatment and for 5 months after the end of treatment. ? Patients have prior history or current evidence of osteonecrosis or osteomyelitis of the jaw. ? Patients have active dental or jaw condition which requires oral surgery, including tooth extraction. ? Patients have non-healed dental or oral surgery, including tooth extraction. ? Patients with planned invasive dental procedures for the course of the study. ? Ongoing treatment with denosumab or bisphosphonates
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To demonstrate the antiproliferative and/or pro-apoptotic activity of denosumab in early breast cancer. If the Hypothesis of this study is proven right it will substantiate and provide rationale to the development of denosumab as an ant-cancer drug in breast cancer.;Secondary Objective: • To correlate the antiproliferative/pro-apoptotic activity of denosumab with the expression of RANK, RANKL (protein expression) and RANK/RANKL modified ratio (mRNA). • To characterize the differential antiproliferative/pro-apoptotic activity of denosumab among the different phenotypes of breast cancers. • To characterize the differential antiproliferative/pro-apoptotic activity of denosumab among pre and post menopausal patients, and menstrual cycle in preneoplasic patients;Primary end point(s): The endpoint to evaluate will be changes in the percentage of tumor cells expressing Ki67 and cleaved caspase 3 between Biopsy A and Biopsy B.;Timepoint(s) of evaluation of this end point: Tras el tratamiento en el momento de la cirugia | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): •Ratio modificado: MR={log(RANK) -1.2} / log(RANKL) mRNA •Correlacionar los cambios en Ki67 con la expresión RANKL, RANK (mRNA y proteínas). •Correlacionar los cambios en Ki67 con la expresión de los receptores de estrógenos y progesterona. La seguridad del denosumab y de la realización de las biopsias según los criterios del CTCAE v4.;Timepoint(s) of evaluation of this end point: Tras el tratamiento en el momento de la cirugía | — |
Countries
Spain
Contacts
Public ContactGestora de proyectos
Institut Catala d'Oncologia
Outcome results
None listed